BioMarin Pharmaceutical Balance Sheet
NASDAQ: BMRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BioMarin Pharmaceutical financial position
At the end of fiscal 2025, BioMarin Pharmaceutical reported total assets of $7.59 billion, up 8.7% from a year earlier against total liabilities of $1.51 billion. Shareholders' equity stood at $6.09 billion, or 80.2% of assets. The company held $1.31 billion in cash and equivalents against $597.2 million of debt, a net cash position of $714.5 million.
The current ratio (current assets divided by current liabilities) was 5.21, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.10.
Summary generated from market data by MetaCap's automated system. Methodology
BioMarin Pharmaceutical balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 1.31B | 942.84M | 755.13M | 724.53M | 587.28M | 649.16M | 437.45M | 493.98M | 598.03M | 408.33M |
| Short-Term Investments | 248.93M | 194.86M | 318.68M | 567.01M | 426.60M | 416.23M | 316.36M | 590.33M | 797.94M | 381.35M |
| Receivables | 908.21M | 660.53M | 633.70M | 461.32M | 373.40M | 448.35M | 377.40M | 342.63M | 261.37M | 215.28M |
| Inventory | 1.30B | 1.23B | 1.11B | 894.08M | 776.67M | 698.55M | 680.27M | 530.87M | 475.77M | 355.13M |
| Total Current Assets | 3.95B | 3.23B | 2.96B | 2.75B | 2.27B | 2.34B | 1.94B | 2.06B | 2.21B | 1.42B |
| Property, Plant & Equipment | 952.51M | 1.04B | 1.07B | 1.07B | 1.04B | 1.03B | 1.01B | 948.68M | 896.70M | 798.77M |
| Goodwill | 196.20M | 196.20M | 196.20M | 196.20M | 196.20M | 196.20M | 197.04M | 197.04M | 197.04M | 197.04M |
| Intangible Assets | 213.84M | 255.28M | 294.70M | 338.57M | 388.65M | 417.27M | 456.58M | 491.81M | 517.51M | 553.78M |
| Long-Term Investments | 492.24M | 521.24M | 611.13M | 333.83M | 507.79M | 285.47M | 411.98M | 235.86M | 385.79M | 572.71M |
| Total Assets | 7.59B | 6.99B | 6.84B | 6.38B | 6.00B | 5.85B | 4.69B | 4.43B | 4.63B | 4.02B |
| Accounts Payable | 759.03M | 606.99M | 683.15M | 572.96M | 498.26M | 492.55M | 570.62M | 437.29M | 401.92M | 370.50M |
| Short-Term Debt | 0 | — | — | — | — | — | — | — | — | — |
| Total Current Liabilities | 759.03M | 606.99M | 1.18B | 588.88M | 546.50M | 492.55M | 932.50M | 523.24M | 816.52M | 439.31M |
| Long-Term Debt | 597.18M | — | — | — | — | — | — | — | — | — |
| Total Liabilities | 1.51B | 1.33B | 1.89B | 1.77B | 1.74B | 1.74B | 1.57B | 1.46B | 1.82B | 1.26B |
| Shareholders' Equity | 6.09B | 5.66B | 4.95B | 4.60B | 4.27B | 4.10B | 3.12B | 2.97B | 2.81B | 2.77B |
| Retained Earnings | 154.21M | -194.69M | -621.55M | -789.20M | -930.76M | -861.61M | -1.72B | -1.69B | -1.64B | -1.52B |
| Total Debt | 597.18M | — | — | — | — | — | — | — | — | — |
| Net Cash (Debt) | 963.43M | 1.14B | 1.07B | 1.29B | 1.01B | 1.07B | 753.81M | 1.08B | 1.40B | 789.68M |
| Shares Outstanding | 192.30M | 190.76M | 188.60M | 186.25M | 183.91M | 181.74M | 179.84M | 178.25M | 175.84M | 172.65M |
This table shows 10 annual periods of BioMarin Pharmaceutical's balance sheet, from FY 2025 back to FY 2016, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow BMRN's reporting calendar. What is a balance sheet?